High Pathological Response and Favorable Survival after Presurgical Sequential Lenvatinib-Transarterial Chemoembolization for Resectable Hepatocellular Carcinoma
Presurgical sequential lenvatinib-TACE therapy is a feasible and safe strategy for resectable HCC. This protocol achieved a high pathological response and favorable survival outcomes, suggesting that it may mitigate the risk of early recurrence. Our findings highlight the importance of mALBI grade monitoring for patient selection and provide a rationale for larger, prospective studies.
Authors
- Yoshiyuki Meguro
- Atsushi Miki (ORCID: https://orcid.org/0000-0002-2908-0177)
- Shunji Watanabe
- Kentaro Shimodaira
- Naohiro Sata
- Masatake Taniguchi (ORCID: https://orcid.org/0000-0001-7867-9648)
- Kohei Hamamoto (ORCID: https://orcid.org/0000-0002-6008-6390)
- Naoya Kasahara (ORCID: https://orcid.org/0000-0002-7952-1276)
- Kazuhiro Endo (ORCID: https://orcid.org/0000-0002-2845-3533)
- Hideki Sasanuma
- Yuji Kaneda
- Masanobu Taguchi
- Kazue Morishima
- Hironori Yamaguchi
- Yuichi Aoki
- Naoki Morimoto
- Yasunaru Sakuma
- Yuki Kimura
Institutions
- Jichi Medical University (JP)
Publication Details
- Journal
- Oncology
- Published
- 2025-12-31
- DOI
- https://doi.org/10.1159/000550192
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00